Seelos rises on promising pre-clinical data on Parkinson's therapy

Seelos Therapeutics

07/07/2021 12:56

** Drug developer Seelos Therapeutics' shares  SEEL.O  up
nearly 7% at $3.07 premarket 
    ** Co says its experimental therapy that uses the CRISPR
gene-editing technology reduced levels of a gene tied to
Parkinson's disease in rodents  urn:newsml:reuters.com:*:nPn6wqNvpa
    ** The therapy reduced levels of the SNCA gene, which has
been implicated as a highly significant genetic risk factor for
Parkinson's Disease, according to co
    ** Parkinson's disease is the second-most common
neurodegenerative disorder in the world 
    ** SEEL stock up more than 80% YTD 

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manasmishra24))